Disodium etidronate therapy for dystrophic cutaneous calcification

Area of Science:

• Dermatology
• Rheumatology
• Pharmacology

Background:

• Dystrophic cutaneous calcification can be disabling.
• Scleroderma is a potential co-morbidity.
• Limited treatment options exist for extensive calcification.

Purpose of the Study:

• To evaluate the efficacy of disodium etidronate in a patient with extensive dystrophic cutaneous calcification.
• To assess the impact of disodium etidronate on calcification progression and clinical symptoms.

Main Methods:

• Oral administration of disodium etidronate.
• Clinical observation of calcification changes.
• Assessment of pain, abscess formation, and joint mobility.

Main Results:

• Therapy appeared to arrest and partially reverse calcification progression.
• Deep calcific deposits showed dissipation and partial reabsorption.
• Superficial deposits were halted during treatment.
• Significant reduction in pain, cessation of abscesses, and improved joint mobility were observed.

Conclusions:

• Disodium etidronate may be a viable treatment for disabling dystrophic cutaneous calcification.
• The drug demonstrated potential in managing both the pathological calcification and associated clinical manifestations.